

# Local Production for Access to Medical Products: Developing a Framework to Improve Public Health



Intellectual  
Property and Trade

R&D  
Innovation

Technology  
Transfer

Improving Access

Financing

Monitoring and  
Reporting



World Health  
Organization



# Local Production for Access to Medical Products: Developing a Framework to Improve Public Health



**World Health  
Organization**

This report forms part of the project entitled "Improving access to medicines in developing countries through technology transfer and local production". It is implemented by the Department of Public Health Innovation and Intellectual Property of the World Health Organization (WHO/PHI) in partnership with the United Nations Conference on Trade and Development (UNCTAD) and the International Centre for Trade and Sustainable Development (ICTSD), with funding from the European Union (EU). The overall objective of the project is to increase access – especially for poor people in developing and least developed countries – to medicines, vaccines and diagnostics.

This publication has been produced with the assistance of the European Union. The contents of this publication are the sole responsibility of the World Health Organization and can in no way be taken to reflect the views of the European Union.

Editing and design by Inís Communication – <http://www.iniscommunication.com>

#### WHO Library Cataloguing-in-Publication Data

Local production for access to medical products: developing a framework to improve public health.

1. Essential drugs. 2. Vaccines. 3. Diagnosis. 4. Technology transfer. 5. Biomedical technology. 6. Developing countries. I. World Health Organization.

ISBN 978 92 4 150289 4

(NLM classification: QV 704)

© **World Health Organization 2011**

All rights reserved. Publications of the World Health Organization are available on the WHO web site ([www.who.int](http://www.who.int)) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [bookorders@who.int](mailto:bookorders@who.int)).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site ([http://www.who.int/about/licensing/copyright\\_form/en/index.html](http://www.who.int/about/licensing/copyright_form/en/index.html)).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Photo: WHO / Evelyn Hockstein  
Printed in France

# Contents

<b>Abbreviations</b>	<b>1</b>
<b>Acknowledgements</b>	<b>2</b>
<b>1. Introduction</b>	<b>3</b>
<b>2. Setting the context, background and definition of key concepts of local production, technology transfer and access to medical products in developing countries</b>	<b>5</b>
2.1 Setting the context	5
2.2 Brief historical background	8
2.3 Definition and understanding of key concepts	9
2.3.1 "Access to medicines" and medical products	9
2.3.2 Essential medicines	10
2.3.3 Local production	11
2.3.4 Developing countries and definition by low to high income	13
2.3.5 Technology transfer	14
<b>3. Overview of local production, technology transfer and access to medical products in developing countries</b>	<b>16</b>
3.1 Arguments and evidence relating to local production and access to medical products	16
3.1.1 Overview	16
3.1.2 Barriers to local production are numerous and varied	17
3.1.3 Evidence from the literature on links between local production and access	18
3.1.4 Activities of Phase 1 of the project on improving access to medical products through local production	21
3.1.5 Discussion of common themes on local production, technology transfer and access to medical products	26
3.2 Common findings from Phase 1 actions on local production, technology transfer and access to medical products	32
3.2.1 Local production is growing in developing countries	32
3.2.2 Technology transfer is an important factor in coping with barriers to enable local production	33
3.2.3 Intellectual property rights are important for decisions on local production and technology transfer	33
3.2.4 Local production has the potential to improve access to medical products	34
<b>4. The need for a policy framework for local production and access to medical products in developing countries</b>	<b>37</b>
4.1 Why a policy framework for local production and access to medical products in developing countries is needed	38
4.2 The industrial policy perspective: Factors of relevance for local production	41
4.3 The health policy perspective: Key factors to ensure access to medical products	43
4.3.1 Universal access to medical products	44
4.3.2 Availability of essential medical products	45
4.3.3 Affordable prices	46
4.3.4 Quality assurance and regulatory support	47
4.3.5 Uninterrupted supply of medicines	49
4.3.6 Rational selection and rational use of medical products	49



<b>5. Building a framework for government support for local production and access to medical products</b>	<b>50</b>
5.1 The shared goals of industrial and health policies for local production and improvement in access to medical technology	50
5.1.1 Policies to ensure strategic selection of essential medical products for local production.	50
5.1.2 Policies to enable pricing of locally produced medical products that governments and people can afford	51
5.1.3 Policies to ensure strict compliance to quality standards by manufacturers and effective national medicine regulatory authorities	52
5.1.4 Policies that ensure health security – an uninterrupted supply of essential medical products	52
5.1.5 Innovation policies for development of formulations more suitable for local conditions	52
5.2 Government Support to local production for improving access to medical products	54
5.3 Direct government support to the local manufacturers of essential medical products..	54
5.3.1 Policies that reduce the cost of manufacture	54
5.4 Indirect government support to the local manufacturers of essential medical products	55
5.4.1 Invest in strengthening national medical products' regulation	55
5.4.2 Develop national priority lists of medical products list.	55
5.4.3 Improve the financing of health services for expanding the domestic market	55
5.4.4 Facilitate access to foreign markets.	56
5.4.5 Facilitate development of regional pooled procurement mechanisms	56
5.4.6 Encourage regulatory harmonization	56
5.4.7 Introduce appropriate pricing policies:.	56
5.4.8 Facilitate relevant transfer of technology	57
5.4.9 Support incremental innovation and production:	57
5.4.10 Develop appropriate intellectual property regimes	58
5.4.11 Develop appropriate investment policies and facilitate joint ventures	59
5.4.12 Facilitate international cooperation for local production	60
<b>6. The way forward: Using the framework to advance industrial and health policy goals with regard to local production</b>	<b>61</b>
6.1 Policy analysis for policy coherence	61
6.2 Development of global resources on local production, technology transfer and access to medical products	62
6.3 Advocacy for policy framework for local production and access to essential medical products	62
6.4 Capacity-building and technical assistance for local production of selected essential medical products	63
<b>7. Conclusions</b>	<b>64</b>
<b>References</b>	<b>65</b>

## Abbreviations

AIDS	acquired immunodeficiency syndrome
API	active pharmaceutical ingredient
ARV	antiretroviral medicine
CIPHI	Commission on Intellectual Property Rights, Innovation and Public Health
DCVMN	Developing Countries Vaccine Manufacturers Network
DNDi	Drugs for Neglected Diseases Initiative
EPI	Expanded Programme on Immunization
GAVI	Global Alliance for Vaccines and Immunisation
GMP	good manufacturing practices
GNI	gross national income
GSPA-PHI	Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property
HIV	human immunodeficiency virus
ICTSD	International Centre for Trade and Sustainable Development
LDC	least-developed country
NGO	nongovernmental organization
PEPFAR	United States President's Emergency Plan for AIDS Relief
R&D	research and development
TB	tuberculosis
TRIPS	trade-related aspects of intellectual property rights
UN	United Nations
UNCTAD	United Nations Conference on Trade and Development
UNICEF	United Nations Children's Fund
UNIDO	United Nations Industrial Development Organization
WHO	World Health Organization
WTO	World Trade Organization

## Acknowledgements

Lead authors:

Padmashree Gehl Sampath, Science, Technology and ICT Branch, Division on Technology and Logistics, UNCTAD

Zafar Mirza, Department of Public Health, Innovation and Intellectual Property, Innovation, Information, Evidence and Research, WHO

Kiyoshi Adachi, Intellectual Property Unit, Investment Capacity-Building Branch, Division on Investment and Enterprise, UNCTAD

Robert Terry, Department of Public Health, Innovation and Intellectual Property, Innovation, Information, Evidence and Research cluster, WHO

With additional contributions from:

Frederick M Abbott, College of Law, Florida State University

Warren A Kaplan, Department of International Health, Boston University School of Public Health

Martin Friede, Innovation, Information Evidence and Research, WHO

Richard Laing, Medicines Policy, Essential Drugs and Traditional Medicine, Health Systems and Services, WHO

Ruth McNerney, London School of Hygiene & Tropical Medicine

Rosanna Peeling, London School of Hygiene & Tropical Medicine

Erin Sparrow, Innovation, Information Evidence and Research, WHO

Pedro Roffe, Senior Associate, Programme on Innovation, Technology and Intellectual Property, ICTSD

Christoph Spennemann, Intellectual Property Unit, Investment Capacity-Building Branch, Division on Investment and Enterprise, UNCTAD

The text was reviewed and commented on by:

Wilbert Bannenberg, Public Health Consultant, Borseijk, the Netherlands

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_28708](https://www.yunbaogao.cn/report/index/report?reportId=5_28708)

